Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1

被引：87

作者：

Choi, Michael Y. ^{[1
]}

Widhof, George F., II ^{[1
]}

Wu, Christina C. N. ^{[1
]}

Cui, Bing ^{[1
]}

Lao, Fitzgerald ^{[1
]}

Sadarangani, Anil ^{[1
,2
]}

Cavagnaro, Joy ^{[3
]}

Prussak, Charles ^{[1
]}

Carson, Dennis A. ^{[1
]}

Jamieson, Catriona ^{[1
,2
]}

Kipps, Thomas J. ^{[1
]}

机构：

[1] Univ Calif San Diego, Dept Med, Div Hematol Oncol, La Jolla, CA 92093 USA

[2] Univ Calif San Diego, Div Regenerat Med, La Jolla, CA 92093 USA

[3] Access Bio, Boyce, VA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2015年 / 15卷

基金：

美国国家卫生研究院;

关键词：

AKT; cancer stem cell; Cirmtuzumab; CLL; Wnt receptor; CHRONIC LYMPHOCYTIC-LEUKEMIA; ANTIGEN ROR1; EXPRESSION; RECEPTOR; PSEUDOKINASE; PHENOTYPE; FAMILY; CLL;

D O I：

10.1016/j.clml.2015.02.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncoembryonic antigen. Because of its expression on the cell surface of leukemia cells from patients with chronic lymphocytic leukemia (CLL), but not on normal B-cells or other postpartum tissues, ROR1 is an attractive candidate for targeted therapies. UC-961 is a first-in-class humanized monoclonal antibody that binds the extracellular domain of ROR1. In this article we outline some of the preclinical studies leading to an investigational new drug designation, enabling clinical studies in patients with CLL. (C) 2015 The Authors. Published by Elsevier Inc.

引用

页码：S167 / S169

页数：3

共 4 条

[1] APhase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers
Lassen, Ulrik N.
Meulendijks, Didier
Siu, Lilian L.
Karanikas, Vaios
Mau-Sorensen, Morten
Schellens, Jan H. M.
Jonker, Derek J.
Hansen, Aaron R.
Simcox, Mary E.
Schostack, Kathleen J.
Bottino, Dean
Zhong, Hua
Roessler, Markus
Vega-Harring, Suzana M.
Jarutat, Tiantom
Geho, David
Wang, Ka
DeMario, Mark
Goss, Glenwood D.
CLINICAL CANCER RESEARCH, 2015, 21 (02) : 258 - 266
[2] Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors
Lam, Elaine T.
Eckhardt, S. Gail
Messersmith, Wells
Jimeno, Antonio
O'Bryant, Cindy L.
Ramanathan, Ramesh K.
Weiss, Glen J.
Chadha, Manpreet
Oey, Abbie
Ding, Han Ting
Culp, Patricia A.
Keller, Stephan F.
Zhao, Vivian Y.
Tsao, L. Claire
Singhal, Anil
Holen, Kyle D.
Von Hoff, Daniel
MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01) : 215 - 221
[3] MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study
Hong, David S.
Hui, David
Bruera, Eduardo
Janku, Filip
Naing, Aung
Falchook, Gerald S.
Piha-Paul, Sarina
Wheler, Jennifer J.
Fu, Siqing
Tsimberidou, Apostolia M.
Stecher, Michael
Mohanty, Prasant
Simard, John
Kurzrock, Razelle
LANCET ONCOLOGY, 2014, 15 (06) : 656 - 666
[4] Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer
Ogier, Charline
Colombo, Pierre-Emmanuel
Bousquet, Corinne
Canterel-Thouennon, Lucile
Sicard, Pierre
Garambois, Veronique
Thomas, Gaelle
Gaborit, Nadege
Jarlier, Marta
Pirot, Nelly
Pugniere, Martine
Vie, Nadia
Gongora, Celine
Martineau, Pierre
Robert, Bruno
Pelegrin, Andre
Chardes, Thierry
Larbouret, Christel
CANCER LETTERS, 2018, 432 : 227 - 236

← 1 →